Cell metab:想减肥?到底应该少吃饭还是少吃肉?

2015-08-19 佚名 生物谷

近日,来自美国美国国立卫生研究院的研究人员进行了一项最新研究,对减少碳水化合物或脂肪摄入如何影响身体的脂肪含量进行了研究,相关研究结果发表在国际学术期刊cell metabolism上。目前关于减少碳水化合物还是减少脂肪摄入对体重减轻有更大影响存在很多争论,但一直没有人对维持脂肪摄入的同时减少碳水化合物摄入或发生相反情况会对体重变化带来什么样的影响进行准确衡量。来自美国NIH的Kevin Hall



近日,来自美国国立卫生研究院的研究人员进行了一项最新研究,对减少碳水化合物或脂肪摄入如何影响身体的脂肪含量进行了研究,相关研究结果发表在国际学术期刊cell metabolism上。

目前关于减少碳水化合物还是减少脂肪摄入对体重减轻有更大影响存在很多争论,但一直没有人对维持脂肪摄入的同时减少碳水化合物摄入或发生相反情况会对体重变化带来什么样的影响进行准确衡量。

来自美国NIH的Kevin Hall建立了一种数学模型对上述问题进行了模拟,结果发现只限制碳水化合物的摄入会引起身体燃烧掉的脂肪量发生变化,而减少脂肪摄入则会导致全身性的脂肪减少。但这一模型一直缺少人类研究数据进行验证。

研究饮食对体重的影响经常存在饮食量的测量难题,研究参与者可能并不会坚持研究人员制定的饮食计划,或者对饮食量存在错误判断,甚至还会在研究的跟踪调查中表现出不诚实行为。为解决这一问题,研究人员将同意参加研究的19名肥胖病人置于能够检测各项代谢指标的代谢仓中,对病人摄取食物的过程进行密切观察和控制。

在对两种不同饮食进行研究之后证明之前建立的数学模型得出的结论是正确的。虽然限制饮食中的碳水化合物会燃烧掉更多的身体脂肪,但限制饮食中的脂肪摄入会对减少身体脂肪带来更大影响。根据模型预测,若将实验周期延长,即使饮食中包含相同能量,只有碳水化合物和脂肪的比例不同,机体仍会减小不同饮食计划造成的身体脂肪差异。

研究人员指出,这项研究表明,减少碳水化合物摄入和减少脂肪摄入对减重的影响并不相同,但从长期来看,两者造成的影响非常相近。因此他们建议,最好的饮食方案就是你能够坚持下去的饮食方案,他们将在未来进行更深一步研究。

原文链接:

Kevin D. et al.Calorie for Calorie, Dietary Fat Restriction Results in More Body Fat Loss than Carbohydrate Restriction in People with Obesity.cell metabolism.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895822, encodeId=3a1c189582258, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Apr 04 17:12:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869192, encodeId=e1bc18691920d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 04 00:12:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959447, encodeId=a4f1195944ef9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jan 08 08:12:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887455, encodeId=c033188e45518, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Nov 19 17:12:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35938, encodeId=74e93593852, content=好吧…结论不出意外!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Aug 22 00:05:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2016-04-04 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895822, encodeId=3a1c189582258, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Apr 04 17:12:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869192, encodeId=e1bc18691920d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 04 00:12:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959447, encodeId=a4f1195944ef9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jan 08 08:12:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887455, encodeId=c033188e45518, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Nov 19 17:12:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35938, encodeId=74e93593852, content=好吧…结论不出意外!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Aug 22 00:05:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895822, encodeId=3a1c189582258, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Apr 04 17:12:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869192, encodeId=e1bc18691920d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 04 00:12:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959447, encodeId=a4f1195944ef9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jan 08 08:12:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887455, encodeId=c033188e45518, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Nov 19 17:12:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35938, encodeId=74e93593852, content=好吧…结论不出意外!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Aug 22 00:05:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2016-01-08 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1895822, encodeId=3a1c189582258, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Apr 04 17:12:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869192, encodeId=e1bc18691920d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 04 00:12:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959447, encodeId=a4f1195944ef9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jan 08 08:12:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887455, encodeId=c033188e45518, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Nov 19 17:12:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35938, encodeId=74e93593852, content=好吧…结论不出意外!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Aug 22 00:05:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-11-19 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1895822, encodeId=3a1c189582258, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Apr 04 17:12:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869192, encodeId=e1bc18691920d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 04 00:12:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959447, encodeId=a4f1195944ef9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jan 08 08:12:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887455, encodeId=c033188e45518, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Nov 19 17:12:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35938, encodeId=74e93593852, content=好吧…结论不出意外!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Aug 22 00:05:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-08-22 Jianghuiqin

    好吧…结论不出意外!

    0

相关资讯

Arthritis Rheumatol:关于类风湿性关节炎的肥胖悖论和死亡风险

目的:与一般人群中观察的相比,较低的身体质量指数(BMI)与类风湿性关节炎(RA)患者上升的死亡率有关。本研究的目的是评估减肥是否可以解释这些看似矛盾的观察。方法:我们的研究包括登记的退伍军人事务部(弗吉尼亚州)类风湿性关节炎RA的患者。死亡日期摘取自弗吉尼亚州的电子医疗记录。身体质量指数BMI在每个研究拜访期和先前拜访的变化进行测量。每个患者最大的体重指数也从病历中获取。在前面的13个月内,体重

Am J Public Health:严重肥胖者减肥不易

严重肥胖的人若想达到正常体重似乎是遥不可及的梦想,只有1/1290的男性和1/677的女性成功减肥。本文第一作者是来自国王学院健康和保健研究专业的Alison Fildes,他表示,身体重量减轻5-10%已被证实好处多多,这也被认作是减肥的目标。但是他强调肥胖的人即便希望体重减轻较少都是困难的。他认为,肥胖患者的主要治疗手段是体重管理方案的这个观点已不适用于大多数肥胖患者。在这项研究中,研究人员收

绿茶为什么能减肥?

绿茶是一种十分常见的对身体健康有益的饮品,不过关于绿茶如何促进人体健康的机理一直没有被大家搞明白。不过其中一项好处就是饮用绿茶能够促进减肥,最近科学家大概搞明白了绿茶是如何帮助我们增强减肥效果的:来自波兰的一队科学家发现绿茶促进减肥的秘密在于——淀粉。Jaroslaw Walkowiak 是波兹南医科大(Poznan University of Medical Sciences)的一名研究人员,他

Cell Metabolism:想减肥?低脂饮食效果更好

说到减肥,大家都想知道哪种饮食才是最好和最有效的饮食,既能够有效减少机体脂肪,又不会为机体带来副作用。研究人员通过比较低脂饮食和低碳水化合物饮食,他们发现,低脂饮食更能有效减少体内脂肪。研究人员进行了一项规模虽小但十分缜密的试验,在病房内选取了19名肥胖患者,观察他们两周内的体重变化情况,并将研究结果发表在Cell Metabolism杂志上。Kevin Hall是NIDDK的代谢学研究人员,他认

Int J Obes:烟民戒烟后体重普遍增加(NHANES研究)

据州立大学医学院的研究人员称,对于吸烟者来说,每天吸烟的数量和当前的BMI是预测戒烟后体重增长的有效指标。戒烟后可能会导致戒烟者体重增加,但增重多少因人而异。既往研究表明,对于某些人来说只会几磅,但对其他人来说,增重可以超过25磅。但是,有助于预测吸烟者的戒烟后体重的增加并不被人理解和接受。“很多人都担心戒烟后体重增加,这是他们心里难以逾越的障碍,他们在纠结要不要为了戒烟而增重,”宾州州立大学医学

JAMA Oncol:绝经后女性运动时长超300分钟/天,可有效减肥和避免乳腺癌

体育活动是一种廉价、无创的疾病预防策略。世界卫生组织建议,若想拥有一个健康的身体,我们每周至少进行150分钟中等强度的体育锻炼,或每周进行60-75分钟高强度的体育锻炼。加拿大阿尔伯塔省卫生服务组织的Christine Friedenreich教授即本文的作者,她认为:对于之前不进行锻炼的绝经后的肥胖女性来说,1年内每周进行300分钟中到高强度锻炼,较每周进行150分钟锻炼的女性而言可以明显减少脂